Translational Medicine, Sidra Medicine, P.O. Box 26999, Doha, Qatar.
Department of Biomedical Science, College of Health Sciences, Qatar University, Doha, Qatar.
Mol Cancer. 2020 Mar 12;19(1):57. doi: 10.1186/s12943-020-01175-9.
Early-stage detection of leukemia is a critical determinant for successful treatment of the disease and can increase the survival rate of leukemia patients. The factors limiting the current screening approaches to leukemia include low sensitivity and specificity, high costs, and a low participation rate. An approach based on novel and innovative biomarkers with high accuracy from peripheral blood offers a comfortable and appealing alternative to patients, potentially leading to a higher participation rate.Recently, non-coding RNAs due to their involvement in vital oncogenic processes such as differentiation, proliferation, migration, angiogenesis and apoptosis have attracted much attention as potential diagnostic and prognostic biomarkers in leukemia. Emerging lines of evidence have shown that the mutational spectrum and dysregulated expression of non-coding RNA genes are closely associated with the development and progression of various cancers, including leukemia. In this review, we highlight the expression and functional roles of different types of non-coding RNAs in leukemia and discuss their potential clinical applications as diagnostic or prognostic biomarkers and therapeutic targets.
早期发现白血病是成功治疗该疾病的关键决定因素，可提高白血病患者的生存率。目前白血病筛查方法存在的局限性因素包括灵敏度和特异性低、成本高、参与率低。基于外周血中具有高准确性的新型创新生物标志物的方法为患者提供了一种舒适且有吸引力的选择，可能会导致更高的参与率。最近，非编码 RNA 由于参与分化、增殖、迁移、血管生成和凋亡等重要致癌过程，作为白血病的潜在诊断和预后生物标志物受到了广泛关注。新出现的证据表明，非编码 RNA 基因的突变谱和失调表达与各种癌症（包括白血病）的发生和发展密切相关。在这篇综述中，我们强调了不同类型非编码 RNA 在白血病中的表达和功能作用，并讨论了它们作为诊断或预后生物标志物和治疗靶点的潜在临床应用。
